Solid Biosciences (SLDB) Stock Overview
Develops therapies for neuromuscular and cardiac diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SLDB Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Solid Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.54 |
| 52 Week High | US$11.45 |
| 52 Week Low | US$3.79 |
| Beta | 2.44 |
| 1 Month Change | 7.80% |
| 3 Month Change | 33.61% |
| 1 Year Change | 79.66% |
| 3 Year Change | 192.64% |
| 5 Year Change | -76.18% |
| Change since IPO | -97.19% |
Recent News & Updates
Solid Biosciences: The Bull Case Is No Longer Just Duchenne
Summary Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset rare disease platform with clinical validation momentum. SLDB’s $380.7M cash position funds operations into 2028, supporting high-cost Phase 3 SGT-003 trials and multiple pipeline programs without near-term dilution risk. SGT-003’s Phase 1/2 data show strong microdystrophin expression and safety, while additional programs in Friedreich’s ataxia and CPVT expand addressable markets. Valuation hinges on SLDB’s ability to convert promising biomarkers into functional benefits; clinical execution, safety, and competition remain key risks. Read the full article on Seeking AlphaIs Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Recent updates
Shareholder Returns
| SLDB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.4% | -4.4% | -0.2% |
| 1Y | 79.7% | 39.9% | 14.8% |
Return vs Industry: SLDB exceeded the US Biotechs industry which returned 39.9% over the past year.
Return vs Market: SLDB exceeded the US Market which returned 14.8% over the past year.
Price Volatility
| SLDB volatility | |
|---|---|
| SLDB Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SLDB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SLDB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 121 | Bo Cumbo | www.solidbio.com |
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases.
Solid Biosciences Inc. Fundamentals Summary
| SLDB fundamental statistics | |
|---|---|
| Market cap | US$1.02b |
| Earnings (TTM) | -US$207.10m |
| Revenue (TTM) | n/a |
Is SLDB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLDB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$207.10m |
| Earnings | -US$207.10m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLDB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 22:09 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Solid Biosciences Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Timothy Chiang | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Charles Duncan | Cantor Fitzgerald & Co. |